Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent trials have studied higher dosages of omega-3 fatty acids, reporting a cardiovascular benefit in 2 trials of purified EPA. 10,11”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [11]
In the citing paper
“O3CA lowered non-HDL-C by 6% and apo B by 2%, 41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“With regard to O3CA, the 2-g/d dose examined in the ESPRIT trial (Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol; ≈1.5 g/d EPA+DHA) reduced triglycerides by 9% versus 15% with 4 g/d.41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“High‐dose eicosapentaenoic ethyl ester combined with baseline statins can lead to a remarkable decline in first and recurrent events in high‐risk patients with hypertriglyceridemia. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
In the citing paper
“Conversely, patients with hypertriglyceridemia treated with a medium‐to‐high dose of icosapent ethyl were less likely to develop ischemic events, including CVD death. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
126 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Cited by
Items 301–400 of 1,052
Remnant lipoproteins: are they equal to or more atherogenic than LDL?
Salinas, C. A. A., & Chapman, M. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000682 · Cited by 87
Doi, T., Langsted, A., & Nordestgaard, B. G. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab555 · Cited by 87
Cyclooxygenases and the cardiovascular system
Mitchell, J. A., Kirkby, N. S., Ahmetaj‐Shala, B., Armstrong, P. C. J., Crescente, M., Ferreira, P., Pires, M. E. L., Vaja, R., & Warner, T. D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107624 · Cited by 94
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Self-citationDyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 98
Resolution metabolomes activated by hypoxic environment
Norris, P. C., Libreros, S., & Serhan, C. N. (2019) · Science Advances · doi:10.1126/sciadv.aax4895 · Cited by 90
Chen, Y., Chang, Z., Liu, Y., Zhao, Y., Fu, J., Zhang, Y., Liu, Y., & Fan, Z. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.11.005 · Cited by 101
Gevaert, A. B., Adams, V., Bahls, M., Bowen, T. S., Cornelissen, V., Dörr, M., Hansen, D., Kemps, H., Leeson, P., Craenenbroeck, E. M. V., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319877716 · Cited by 90
Green, C. J., Pramfalk, C., Charlton, C. A., Gunn, P. J., Cornfield, T., Pavlides, M., Karpe, F., & Hodson, L. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000871 · Cited by 84
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 89
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Martin, A., Lang, S., Goeser, T., Demir, M., Steffen, H., & Kasper, P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01028-4 · Cited by 106
Highlighting Residual Atherosclerotic Cardiovascular Disease Risk
Matsuura, Y., Kanter, J. E., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311999 · Cited by 94
Ruscica, M., Zimetti, F., Adorni, M. P., Sirtori, C. R., Lupo, M. G., & Ferri, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104653 · Cited by 82
Ajabnoor, S. M., Thorpe, G., Abdelhamid, A. S., & Hooper, L. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02413-y · Cited by 91
Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
Baratta, F., Cocomello, N., Coronati, M., Ferro, D., Pastori, D., Angelico, F., & Ben, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054268 · Cited by 94
The Effects of Fish Oil on Cardiovascular Diseases: Systematical Evaluation and Recent Advance
Liao, J., Xiong, Q., Yin, Y., Ling, Z., & Chen, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.802306 · Cited by 98
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 80
EPA and DHA in microalgae: Health benefits, biosynthesis, and metabolic engineering advances
Jesionowska, M., Ovadia, J., Hockemeyer, K., Clews, A. C., & Xu, Y. (2023) · Journal of the American Oil Chemists Society · doi:10.1002/aocs.12718 · Cited by 92
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
Self-citationBoden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz778 · Cited by 72
Self-citationTriglycerides and cardiovascular disease
Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 81
Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes
Neves, J. S., Newman, C. B., Bostrom, J., Buysschaert, M., Newman, J. D., Medina, J. L., Goldberg, I. J., & Bergman, M. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109980 · Cited by 99
Residual cardiovascular risk: When should we treat it?
Gómez-Delgado, F., Raya‐Cruz, M., Katsiki, N., Delgado‐Lista, J., & Pérez‐Martínez, P. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.013 · Cited by 92
Ray, K. K., Oru, E., Rosenson, R. S., Jones, J., Ma, X., Walgren, J., Haupt, A., Verma, S., Gaudet, D., Nicholls, S. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00507-0 · Cited by 81
Artiach, G., Carracedo, M., Plunde, O., Wheelock, C. E., Thul, S., Sjövall, P., Franco-Cereceda, A., Laguna-Fernandez, A., Arnardottir, H., & Bäck, M. (2020) · Circulation · doi:10.1161/circulationaha.119.041868 · Cited by 78
Dietary patterns, dietary nutrients and cardiovascular disease
Nestel, P. J., & Mori, T. A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2301017 · Cited by 107
Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health
Rodriguez, D., Lavie, C. J., Elagizi, A., & Milani, R. V. (2022) · Nutrients · doi:10.3390/nu14235146 · Cited by 81
“, in the REDUCE-IT trial [5], used four times the dose of Ω3FAs (IPE 2 g twice daily) used in the VITAL trial.”
BackgroundMethodInfluentialYang, X. H., Zhang, B. L., Cheng, Y., Fu, S. K., & Jin, H. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.012 · Cited by 78
Current state and future perspective of cardiovascular medicines derived from natural products
Zhao, C., Li, S., Zhang, J., Huang, Y., Zhang, L., Zhao, F., Du, X., Hou, J., Zhang, T., Shi, C.-J., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107698 · Cited by 85
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 79
Bae, J. H., Lim, H., & Lim, S. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.03.014 · Cited by 78
Advances toward precision medicine for bipolar disorder: mechanisms & molecules
Haggarty, S. J., Karmacharya, R., & Perlis, R. H. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0831-4 · Cited by 78
Atar, D., Jukema, J. W., Molemans, B., Taub, P. R., Goto, S., Mach, F., Olmos, C. C., Underberg, J. A., KEECH, A. C., Tokgözoğlu, L. S., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.12.013 · Cited by 90
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Cho, S. M. J., Koyama, S., Honigberg, M. C., Surakka, I. L., Haidermota, S., Ganesh, S., Patel, A. P., Bhattacharya, R., Lee, H., Kim, H. C., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad380 · Cited by 83
Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis
Lorey, M. B., Öörni, K., & Kovanen, P. T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.841545 · Cited by 96
Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression
Bazinet, R. P., Metherel, A. H., Chen, C. T., Shaikh, S. R., Nadjar, A., Joffre, C., & Layé, S. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.07.001 · Cited by 83
Monocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
Nissen, S. E., Lincoff, A. M., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Ridker, P. M., Ray, K. K., McGuire, D. K., Mozaffarian, D., Koenig, W., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1157 · Cited by 76
Self-citationVitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence
Manson, J. E., Bassuk, S. S., Cook, N. R., Lee, I.-M. M., Mora, S., Albert, C. M., & Buring, J. E. (2020) · Circulation Research · doi:10.1161/circresaha.119.314541 · Cited by 84
Tomaszewski, N., He, X., Solomon, V., Lee, M., Mack, W. J., Quinn, J. F., Braskie, M. N., & Yassine, H. N. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-191017 · Cited by 76
Budoff, M. J., Muhlestein, J. B., Bhatt, D. L., Le Pa, V. T., May, H. T., Shaikh, K., Shekar, C., Kinninger, A., Lakshmanan, S., Roy, S. K., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa184 · Cited by 76
Self-citationDenimal, D. (2023) · Antioxidants · doi:10.3390/antiox13010057 · Cited by 93
Libreros, S., Shay, A. E., Nshimiyimana, R., Fichtner, D., Martin, M. J., Wourms, N., & Serhan, C. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.631319 · Cited by 80
Optimal Medical Management of Asymptomatic Carotid Stenosis
Hackam, D. G. (2021) · Stroke · doi:10.1161/strokeaha.120.033994 · Cited by 80
Sascău, R. A., Clément, A., Radu, R., Prisacariu, C., & Stătescu, C. (2021) · Nutrients · doi:10.3390/nu13061774 · Cited by 84
Wang, T., Zhang, X., Zhou, N., Shen, Y., Li, B., Chen, B. E., & Li, X. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029512 · Cited by 73
FISHing for the Miracle of Eicosapentaenoic Acid
Kastelein, J. J. P., & Stroes, E. S. G. (2019) · New England Journal of Medicine · doi:10.1056/nejme1814004 · Cited by 74
Majithia, A., Bhatt, D. L., Friedman, A. N., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055560 · Cited by 74
Self-citationHiram, R., Xiong, F., Naud, P., Xiao, J., Sirois, M. G., Tanguay, J., Tardif, J., & Nattel, S. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa186 · Cited by 81
Self-citationArnardottir, H. H., Pawelzik, S., Öhlund‐Wistbacka, U., Artiach, G., Hofmann, R., Reinholdsson, I., Braunschweig, F., Tornvall, P., Religa, D., & Bäck, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.624657 · Cited by 78
Macrophage Responses to Environmental Stimuli During Homeostasis and Disease
Rasheed, A., & Rayner, K. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab004 · Cited by 91
Daïen, C., Czernichow, S., Letarouilly, J.-G., Nguyen, Y., Sanchez, P., Sigaux, J., Beauvais, C., Desouches, S., Puillandre, R. L., Rigalleau, V., et al. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105319 · Cited by 93
The potential of polygenic scores to improve cost and efficiency of clinical trials
Fahed, A. C., Philippakis, A., & Khera, A. V. (2022) · Nature Communications · doi:10.1038/s41467-022-30675-z · Cited by 82
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.010 · Cited by 72
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Ballena-Caicedo, J., Zuzunaga-Montoya, F. E., Loayza-Castro, J. A., Vásquez-Romero, L. E. M., Tapia‐Limonchi, R., Carrillo, C. I. G. D., & Vera-Ponce, V. J. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01054-3 · Cited by 128
Lipid Abnormalities in Persons Living With HIV Infection
Waters, D. D., & Hsue, P. Y. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.11.005 · Cited by 90
Sakamoto, A., Saotome, M., Iguchi, K., & Maekawa, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164025 · Cited by 73
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 104
Triglyceride-rich lipoproteins and cardiovascular diseases
Xu, D., Xie, L., Cheng, C., Xue, F., & Sun, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1409653 · Cited by 73
“…(EPA) treatment given to high-risk ASCVD patients with well-controlled LDL-C levels but elevated TG levels after statin treatment reduced serum TG levels by only 2%, ApoB levels (re fl ecting LDL-C levels) by 9.7% and the major cardiovascular event risk by 25% compared to the placebo group (94).”
BackgroundInfluentialPatel, S. B., Wyne, K. L., Afreen, S., Belalcazar, L. M., Bird, M. D., Coles, S., Marrs, J. C., Peng, C. C., Pulipati, V. P., Sultan, S., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.016 · Cited by 85
JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease
Nakamura, M., Yaku, H., Ako, J., Arai, H., Asai, T., Chikamori, T., Daida, H., Doi, K., Fukui, T., Ito, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-20-1282 · Cited by 118
Modification of lipoprotein metabolism and function driving atherogenesis in diabetes
Luciani, L., Pedrelli, M., & Parini, P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117545 · Cited by 72
Omega-3 Fatty Acids and Adipose Tissue: Inflammation and Browning
Kalupahana, N. S., Goonapienuwala, B. L., & Moustaid-Moussa, N. (2020) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-122319-034142 · Cited by 72
The Role of Antioxidants Supplementation in Clinical Practice: Focus on Cardiovascular Risk Factors
Cammisotto, V., Nocella, C., Bartimoccia, S., Sanguigni, V., Francomano, D., Sciarretta, S., Pastori, D., Peruzzi, M., Cavarretta, E., D’Amico, A., et al. (2021) · Antioxidants · doi:10.3390/antiox10020146 · Cited by 87
Tikkanen, E., Jägerroos, V., Rodosthenous, R. S., Holmes, M. V., Sattar, N. A., Ala‐Korpela, M., Jousilahti, P., Lundqvist, A., Perola, M., Salomaa, V. V., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021995 · Cited by 79
Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments
Wolf, M., & Hunziker, P. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09961-y · Cited by 77
Hernandez, P., Passi, N., Modarressi, T., Kulkarni, V., Soni, M., Burke, F., Bajaj, A., & Soffer, D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00962-z · Cited by 71
Jiao, J., Liu, G., Shin, H. J., Hu, F. B., Rimm, E. B., Rexrode, K. M., Manson, J. E., Zong, G., & Sun, Q. (2019) · BMJ · doi:10.1136/bmj.l4009 · Cited by 85
Messina, M. J., Shearer, G. C., & Petersen, K. S. (2021) · Nutrition · doi:10.1016/j.nut.2021.111343 · Cited by 83
Global Trends in the Epidemiology and Management of Dyslipidemia
Liu, T., Zhao, D., & Qi, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216377 · Cited by 62
O'Malley, P. G., Arnold, M. J., Kelley, C., Spacek, L., Buelt, A., Natarajan, S., Donahue, M. P., Vagichev, E., Ballard-Hernandez, J., Logan, A., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4648 · Cited by 70
Generoso, G., Janovsky, C. C. P. S., & Bittencourt, M. S. (2019) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000468 · Cited by 69
Athinarayanan, S. J., Hallberg, S. J., McKenzie, A. L., Lechner, K., King, S., McCarter, J. P., Volek, J. S., Phinney, S. D., & Krauss, R. M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01178-2 · Cited by 68
Lipid Disorders and Metabolic-Associated Fatty Liver Disease
Anwar, S. D., Foster, C., & Ashraf, A. P. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.003 · Cited by 78
Lipid-lowering in diabetes: An update
Chait, A., Eckel, R. H., Vrablík, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 81
Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use
Worthmann, A., Ridder, J., Piel, S., Evangelakos, I., Musfeldt, M., Voß, H., O’Farrell, M., Fischer, A. W., Adak, S., Sundd, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44364-y · Cited by 77
Dyslipidaemia management in pregnant patients: a 2024 update
Lewek, J., Bielecka-Dabrowa, A. M., Toth, P. P., & Banach, M. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae032 · Cited by 89
Arca, M., Veronesi, C., D’Erasmo, L., Borghi, C., Colivicchi, F., De Ferrari, G. M., Desideri, G., Pontremoli, R., Temporelli, P. L., Perrone, V., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015801 · Cited by 69
Lombardi, M., Carbone, S., Del Buono, M. G., Chiabrando, J. G., Vescovo, G. M., Camilli, M., Montone, R. A., Vergallo, R., Abbate, A., Biondi-Zoccai, G., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab008 · Cited by 68
Omega-3 Fatty Acids in Pregnancy—The Case for a Target Omega-3 Index
von Schacky, C. (2020) · Nutrients · doi:10.3390/nu12040898 · Cited by 84
Hilvo, M., Wallentin, L. C., Lakic, T. G., Held, C., Kauhanen, D., Jylhä, A., Lindbäck, J., Siegbahn, A. G., Granger, C. B., Köenig, W., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015258 · Cited by 68
Chapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 67
Grundy, S. M., & Stone, N. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0777 · Cited by 67
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Management of dyslipidemia in adult solid organ transplant recipients
Warden, B. A., & Duell, P. B. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.011 · Cited by 79
Advances in biological therapies for dyslipidemias and atherosclerosis
Valanti, E.-K., Dalakoura-Karagkouni, K., Siasos, G., Kardassis, D., Eliopoulos, A. G., & Sanoudou, D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154461 · Cited by 72
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 81
Therapeutic potential of pro-resolving mediators in diabetic kidney disease
Vartak, T., Godson, C., & Brennan, E. P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113965 · Cited by 72
Puri, R., Bansal, M., Mehta, V., Duell, P. B., Wong, N. D., Iyengar, S., Kalra, D. K., Nair, D. R., Nanda, N. C., Narula, J., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.006 · Cited by 83
Sherratt, S. C. R., Juliano, R. A., & Mason, R. P. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183254 · Cited by 67
Self-citationPrevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
Fan, W., Philip, S., Granowitz, C., Toth, P. P., & Wong, N. D. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00170-x · Cited by 66
Self-citationHypertriglyceridemia—causes, significance, and approaches to therapy
Santos-Baez, L. S., & Ginsberg, H. N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00616 · Cited by 66
Chang, J. P., Chang, S., Yang, H.-T., Chen, H.-T., Chien, Y.-C., Yang, B., Su, H., & Su, K. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.03.012 · Cited by 69
Top 10 dietary strategies for atherosclerotic cardiovascular risk reduction
Sikand, G., & Severson, T. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100106 · Cited by 80
Costabile, G., Vetrani, C., Bozzetto, L., Giacco, R., Bresciani, L., Rio, D. D., Vitale, M., Pepa, G. D., Brighenti, F., Riccardi, G., et al. (2021) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab188 · Cited by 69
Novel emerging therapies in atherosclerosis targeting lipid metabolism
Gupta, M., Blumenthal, C., Chatterjee, S., Bandyopadhyay, D., Jain, V., Lavie, C. J., Virani, S. S., Ray, K. K., Aronow, W. S., & Ghosh, R. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764937 · Cited by 74
Rao, A., Briskey, D. R., Nalley, J. O., & Ganuza, E. (2020) · Nutrients · doi:10.3390/nu12061869 · Cited by 73
Metadata
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland...
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899669642
- Cited by
- 3,317
- References
- 47
- Citations by year
- 2026: 327 · 2025: 354 · 2024: 377 · 2023: 430 · 2022: 427 · 2021: 481 · 2020: 518 · 2019: 362
- FWCI
- 286.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amarin
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid ethyl ester, hypertriglyceridemia, cardiovascular risk reduction, ischemic events, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, unstable angina, statin therapy, omega-3 fatty acids, secondary prevention, triglyceride-lowering therapy, LDL cholesterol, diabetes mellitus
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.